Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Intangibles (2021 - 2023)

Indivior Pharmaceuticals has reported Intangibles over the past 3 years, most recently at $237.0 million for Q4 2023.

  • Quarterly results put Intangibles at $237.0 million for Q4 2023, up 238.57% from a year ago — trailing twelve months through Dec 2023 was $237.0 million (up 238.57% YoY), and the annual figure for FY2023 was $237.0 million, up 238.57%.
  • Intangibles for Q4 2023 was $237.0 million at Indivior Pharmaceuticals, up from $70.0 million in the prior quarter.
  • Over the last five years, Intangibles for INDV hit a ceiling of $237.0 million in Q4 2023 and a floor of $70.0 million in Q4 2022.
  • Median Intangibles over the past 3 years was $82.0 million (2021), compared with a mean of $129.7 million.
  • Biggest five-year swings in Intangibles: decreased 14.63% in 2022 and later soared 238.57% in 2023.
  • Indivior Pharmaceuticals' Intangibles stood at $82.0 million in 2021, then dropped by 14.63% to $70.0 million in 2022, then soared by 238.57% to $237.0 million in 2023.
  • The last three reported values for Intangibles were $237.0 million (Q4 2023), $70.0 million (Q4 2022), and $82.0 million (Q4 2021) per Business Quant data.